Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients

Abstract Dysregulated long noncoding RNAs (lncRNAs) are potential markers of several tumor prognoses. This study aimed to develop a lncRNA expression signature that can predict chemotherapeutic sensitivity for patients with advanced stage and high-grade serous ovarian cancer (HGS-OvCa) treated with...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rong Liu, Ying Zeng, Cheng-Fang Zhou, Ying Wang, Xi Li, Zhao-Qian Liu, Xiao-Ping Chen, Wei Zhang, Hong-Hao Zhou
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2017
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/784dddc7409a4d8882c149dc6129006c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:784dddc7409a4d8882c149dc6129006c
record_format	dspace
spelling	oai:doaj.org-article:784dddc7409a4d8882c149dc6129006c2021-12-02T16:08:23ZLong noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients10.1038/s41598-017-00050-w2045-2322https://doaj.org/article/784dddc7409a4d8882c149dc6129006c2017-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-017-00050-whttps://doaj.org/toc/2045-2322Abstract Dysregulated long noncoding RNAs (lncRNAs) are potential markers of several tumor prognoses. This study aimed to develop a lncRNA expression signature that can predict chemotherapeutic sensitivity for patients with advanced stage and high-grade serous ovarian cancer (HGS-OvCa) treated with platinum-based chemotherapy. The lncRNA expression profiles of 258 HGS-OvCa patients from The Cancer Genome Atlas were analyzed. Results revealed that an eight-lncRNA signature was significantly associated with chemosensitivity in the multivariate logistic regression model, which can accurately predict the chemosensitivity of patients [Area under curve (AUC) = 0.83]. The association of a chemosensitivity predictor with molecular subtypes indicated the excellent prognosis performance of this marker in differentiated, mesenchymal, and immunoreactive subtypes (AUC > 0.8). The significant correlation between ZFAS1 expression and chemosensitivity was confirmed in 233 HGS-OvCa patients from the Gene Expression Omnibus datasets (GSE9891, GSE63885, and GSE51373). In vitro experiments demonstrated that the ZFAS1 expression was upregulated by cisplatin in A2008, HeyA8, and HeyC2 cell lines. This finding suggested that ZFAS1 may participate in platinum resistance. Therefore, the evaluation of the eight-lncRNA signature may be clinically implicated in the selection of platinum-resistant HGS-OvCa patients. The role of ZFAS1 in platinum resistance should be further investigated.Rong LiuYing ZengCheng-Fang ZhouYing WangXi LiZhao-Qian LiuXiao-Ping ChenWei ZhangHong-Hao ZhouNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 7, Iss 1, Pp 1-10 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rong Liu Ying Zeng Cheng-Fang Zhou Ying Wang Xi Li Zhao-Qian Liu Xiao-Ping Chen Wei Zhang Hong-Hao Zhou Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
description	Abstract Dysregulated long noncoding RNAs (lncRNAs) are potential markers of several tumor prognoses. This study aimed to develop a lncRNA expression signature that can predict chemotherapeutic sensitivity for patients with advanced stage and high-grade serous ovarian cancer (HGS-OvCa) treated with platinum-based chemotherapy. The lncRNA expression profiles of 258 HGS-OvCa patients from The Cancer Genome Atlas were analyzed. Results revealed that an eight-lncRNA signature was significantly associated with chemosensitivity in the multivariate logistic regression model, which can accurately predict the chemosensitivity of patients [Area under curve (AUC) = 0.83]. The association of a chemosensitivity predictor with molecular subtypes indicated the excellent prognosis performance of this marker in differentiated, mesenchymal, and immunoreactive subtypes (AUC > 0.8). The significant correlation between ZFAS1 expression and chemosensitivity was confirmed in 233 HGS-OvCa patients from the Gene Expression Omnibus datasets (GSE9891, GSE63885, and GSE51373). In vitro experiments demonstrated that the ZFAS1 expression was upregulated by cisplatin in A2008, HeyA8, and HeyC2 cell lines. This finding suggested that ZFAS1 may participate in platinum resistance. Therefore, the evaluation of the eight-lncRNA signature may be clinically implicated in the selection of platinum-resistant HGS-OvCa patients. The role of ZFAS1 in platinum resistance should be further investigated.
format	article
author	Rong Liu Ying Zeng Cheng-Fang Zhou Ying Wang Xi Li Zhao-Qian Liu Xiao-Ping Chen Wei Zhang Hong-Hao Zhou
author_facet	Rong Liu Ying Zeng Cheng-Fang Zhou Ying Wang Xi Li Zhao-Qian Liu Xiao-Ping Chen Wei Zhang Hong-Hao Zhou
author_sort	Rong Liu
title	Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
title_short	Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
title_full	Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
title_fullStr	Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
title_full_unstemmed	Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
title_sort	long noncoding rna expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients
publisher	Nature Portfolio
publishDate	2017
url	https://doaj.org/article/784dddc7409a4d8882c149dc6129006c
work_keys_str_mv	AT rongliu longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT yingzeng longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT chengfangzhou longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT yingwang longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT xili longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT zhaoqianliu longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT xiaopingchen longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT weizhang longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients AT honghaozhou longnoncodingrnaexpressionsignaturetopredictplatinumbasedchemotherapeuticsensitivityofovariancancerpatients
_version_	1718384538162298880

Long noncoding RNA expression signature to predict platinum-based chemotherapeutic sensitivity of ovarian cancer patients

Ejemplares similares